Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LEU011 |
| Synonyms | |
| Therapy Description |
LEU011 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting NKG2D ligands (NKG2DLs), which potentially induces toxicity in tumor cells expressing NKG2DLs (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LEU011 | LEU-011|LEU 011 | LEU011 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting NKG2D ligands (NKG2DLs), which potentially induces toxicity in tumor cells expressing NKG2DLs (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|